AI Article Synopsis
- Migraine is a common and debilitating condition in children and teens, prompting a review of current medication options for treatment and prevention.
- Recent advancements include FDA approval of triptans for children as young as 6 and a key study on preventive medications.
- Despite improvements in treatment, challenges like high placebo effects complicate effective evidence-based research in this area.
Article Abstract
Importance: Migraine is a disabling and prevalent condition that affects the pediatric and adolescent population. This review describes current acute and preventive migraine pharmacologic therapies for the pediatric and adolescent population.
Observations: Multiple pharmacotherapies that have been used in the treatment of acute headache and prevention in pediatric migraine are reviewed. There have been recent advances in the management of migraines among pediatric and adolescent patients, including US Food and Drug Administration approval of triptans for acute management in children as young as 6 years, and the first prospective, randomized, double-blind, placebo-controlled comparative study of preventive pharmacotherapy in pediatric migraine. A major challenge of evidence-based research in pediatric and adolescent migraine is the significant placebo effect.
Conclusions And Relevance: Although progress is being made in the management of migraines among pediatric and adolescent patients, there remains much work to be done.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamaneurol.2018.0046 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!